Clinical Trial

Efficacy of Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Cystoid Macular Edema Following Cataract Phacoemulsification

Completed Phase 4
View on ClinicalTrials.gov →
Summary
This randomized clinical study evaluated the effectiveness of different postoperative nonsteroidal anti-inflammatory drug (NSAID) regimens in patients undergoing uncomplicated phacoemulsification cataract surgery. Eighty-eight eligible participants were randomly assigned to one of four treatment groups using a simple dice-based randomization procedure: bromfenac 0.09% twice daily for 2 weeks, bromfenac 0.09% twice daily for 4 weeks, diclofenac 0.1% four times daily for 4 weeks, or nepafenac 0.1% three times daily for 4 weeks. All patients received the same standard perioperative care and adjunctive dexamethasone treatment. The primary outcome was central subfield thickness (CST) measured by spectral-domain optical coherence tomography (OCT) at 6 and 12 weeks after surgery. Secondary outcomes included best-corrected distance visual acuity, refraction, and intraocular pressure.
Trial Details
NCT Number NCT07696104
Lead Sponsor Pomeranian Medical University Szczecin
Conditions Pseudophakic Cystoid Macular Edema
Enrollment 88 participants
Start Date 2020-10-14
Primary Completion 2024-05-22 (estimated)
Study Completion 2024-05-22 (estimated)
Updated on ClinicalTrials.gov 2026-07-10